相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors
Simon Leonhard April-Monn et al.
NEUROENDOCRINOLOGY (2021)
Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms
Hiroshi Kondo et al.
CELL REPORTS (2021)
Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids
Jillian Johnson et al.
JOURNAL OF MASS SPECTROMETRY (2020)
A deeper understanding of intestinal organoid metabolism revealed by combining fluorescence lifetime imaging microscopy (FLIM) and extracellular flux analyses
Irina A. Okkelman et al.
REDOX BIOLOGY (2020)
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
Joe T. Sharick et al.
FRONTIERS IN ONCOLOGY (2020)
An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping
Kenta Kawasaki et al.
CELL (2020)
Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Cheri A. Pasch et al.
CLINICAL CANCER RESEARCH (2019)
Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids
Joe T. Sharick et al.
NEOPLASIA (2019)
Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
Po Hien Ear et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2019)
NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism
Wusheng Xiao et al.
ANTIOXIDANTS & REDOX SIGNALING (2018)
Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
Kenta Kawasaki et al.
DISEASE MODELS & MECHANISMS (2018)
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines
Tobias Hofving et al.
ENDOCRINE-RELATED CANCER (2018)
NCCN Guidelines® Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines
Manisha H. Shah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study
Huiying Shi et al.
BMC ENDOCRINE DISORDERS (2018)
Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors
Karen Matsukuma et al.
MODERN PATHOLOGY (2017)
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
Tyler M. Foley et al.
MOLECULAR CANCER RESEARCH (2017)
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Amira Mohamed et al.
ONCOTARGET (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Live cell imaging of mouse intestinal organoids reveals heterogeneity in their oxygenation
Irina A. Okkelman et al.
BIOMATERIALS (2017)
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
Timon Vandamme et al.
BRITISH JOURNAL OF CANCER (2016)
Correlating two-photon excited fluorescence imaging of breast cancer cellular redox state with seahorse flux analysis of normalized cellular oxygen consumption
Jue Hou et al.
JOURNAL OF BIOMEDICAL OPTICS (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors
Alexandria T. Phan et al.
CANCER MEDICINE (2016)
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Optical metabolic imaging quantifies heterogeneous cell populations
Alex J. Walsh et al.
BIOMEDICAL OPTICS EXPRESS (2015)
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
S. N. Payne et al.
ONCOGENESIS (2015)
In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment
Amy T. Shah et al.
NEOPLASIA (2015)
Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response
Alex J. Walsh et al.
PANCREAS (2015)
Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer
Eric E. Gardner et al.
CANCER RESEARCH (2014)
Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer
Alex J. Walsh et al.
CANCER RESEARCH (2014)
Endogenous Two-Photon Fluorescence Imaging Elucidates Metabolic Changes Related to Enhanced Glycolysis and Glutamine Consumption in Precancerous Epithelial Tissues
Antonio Varone et al.
CANCER RESEARCH (2014)
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
Amira Mohamed et al.
ENDOCRINE-RELATED CANCER (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
Pankit Vachhani et al.
PHYSIOLOGICAL GENOMICS (2014)
Separating NADH and NADPH fluorescence in live cells and tissues using FLIM
Thomas S. Blacker et al.
NATURE COMMUNICATIONS (2014)
An automated image processing routine for segmentation of cell cytoplasms in high-resolution autofluorescence images
Alex J. Walsh et al.
MULTIPHOTON MICROSCOPY IN THE BIOMEDICAL SCIENCES XIV (2014)
Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism
Mohamed Rahmani et al.
CANCER RESEARCH (2013)
Optical Metabolic Imaging Identifies Glycolytic Levels, Subtypes, and Early-Treatment Response in Breast Cancer
Alex J. Walsh et al.
CANCER RESEARCH (2013)
Targeting cellular metabolism to improve cancer therapeutics
Y. Zhao et al.
CELL DEATH & DISEASE (2013)
Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System A Comparison of Digital Image Analysis With Manual Methods
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Optical Imaging Using Endogenous Contrast to Assess Metabolic State
Irene Georgakoudi et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 14 (2012)
Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
New Effect Size Rules of Thumb
Shlomo S. Sawilowsky
JOURNAL OF MODERN APPLIED STATISTICAL METHODS (2009)
Everolimus:: an update on the mechanism of action, pharmacokinetics and recent clinical trials
Ana I. Sanchez-Fructuoso
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Clinical pharmacokinetics of everolimus
GI Kirchner et al.
CLINICAL PHARMACOKINETICS (2004)
分享论文
